| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
HEPPSO does not have a specific biological target, as it functions primarily as a biological buffer rather than a direct pharmacological agent. However, its strong binding affinity for copper(II) ions suggests that it may interact with copper-dependent enzymes and proteins. Copper is an essential trace element that serves as a cofactor for various enzymes involved in redox reactions, neurotransmitter synthesis, and iron metabolism. By binding to copper ions, HEPPSO may influence the activity of copper-dependent enzymes and affect cellular copper homeostasis. The compound's low cell membrane permeability ensures that it remains primarily in the extracellular space, making it suitable for maintaining pH in cell culture media and biochemical assays without interfering with intracellular processes.
|
|---|---|
| ln Vitro |
In vitro, HEPPSO is used as an ampholytic separator for creating pH gradients in isoelectric focusing. It shows strong binding affinity for copper(II) ions, with a pKa value of 7.84 at 2.0 mM buffer concentration. The compound is a zwitterionic hydrogen buffer widely used for biological research. It is used as a buffer in biological research and as an efficient separator in protein resolution by isoelectric focusing. In biochemical experiments, it is used to maintain pH in enzyme assays, protein purification, and cell culture media. Its low cell membrane permeability makes it suitable for extracellular applications without affecting intracellular pH.
|
| ln Vivo |
In vivo studies are not performed with HEPPSO, as it is a buffer and not intended for systemic exposure. The compound is not administered to living organisms in research settings. Its low cell membrane permeability ensures that it does not cross biological membranes readily, minimizing systemic exposure. The compound has shown no toxicity for crustaceans and is deemed suitable for toxicological studies. However, comprehensive in vivo studies on the parent compound are not documented.
|
| Enzyme Assay |
Cell-free assays for HEPPSO involve preparing the buffer at the desired pH (7.1-8.5) by dissolving the free acid in water and titrating with sodium hydroxide or potassium hydroxide. The buffer is used as a running buffer for electrophoresis, protein purification, or enzyme assays. The compound's strong binding affinity for copper(II) ions can be studied using various analytical techniques, including potentiometry and spectrophotometry. Its pKa value of 7.84 at 2.0 mM buffer concentration is determined by titration. The buffer's performance in isoelectric focusing is assessed by its ability to maintain a stable pH gradient and resolve proteins.
|
| Cell Assay |
Cellular assays using HEPPSO involve using HEPPSO-containing media for cell culture at pH 7.4 to maintain physiological conditions. Cell viability and function are evaluated in the presence of the buffer. The compound's low cell membrane permeability ensures that it does not affect intracellular pH or cellular processes. In toxicological studies, cells are cultured in HEPPSO-containing media, and various endpoints such as cell viability, proliferation, and function are assessed. The compound's suitability for cell culture applications is evaluated based on its compatibility with cell growth and function.
|
| Animal Protocol |
Animal studies are not conducted with HEPPSO. The compound has shown no toxicity for crustaceans and is deemed suitable for toxicological studies. However, comprehensive in vivo studies on the parent compound are not documented. The compound's low cell membrane permeability and lack of systemic exposure mean that it is not typically evaluated in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for HEPPSO are not applicable, as the compound is a buffer and not intended for systemic exposure. Its low cell membrane permeability ensures that it does not cross biological membranes readily, minimizing absorption and distribution. The compound is typically used in vitro and is not administered to living organisms for pharmacokinetic profiling. For research purposes, the compound is handled as a buffer and not used for systemic administration.
|
| Toxicity/Toxicokinetics |
Toxicological data for HEPPSO indicate no toxicity observed for crustaceans, and it is considered suitable for toxicological studies. The compound is not classified as hazardous. Standard safety precautions for handling buffers apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| References |
[1]. Vasconcelos MT, et, al. Copper(II) complexation properties and surfactant activity of 3-[N, N-bis(2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid and N-(2-Hydroxyethyl)piperazine-N'-2-hydroxypropanesulfonic acid pH buffers which may affect trace metal speciation in in vitro studies. Anal Biochem. 1998 Dec 15; 265(2): 193-201.
[2]. Mash HE, et, al. Complexation of copper by zwitterionic aminosulfonic (good) buffers. Anal Chem. 2003 Feb 1; 75(3): 671-7. |
| Additional Infomation |
HEPPSO is an N-(2-hydroxyethyl)piperazine and an N-(sulfonyl)piperazine.
HEPPSO is a research chemical, not a drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a zwitterionic Good's buffer with a pH range of 7.1-8.5 and exhibits strong binding affinity for copper(II) ions. It is usually used as an ampholytic separator to create a pH gradient in isoelectric focusing and is an efficient separator in protein resolution by isoelectric focusing. It has a pKa value of 7.84 at 2.0 mM buffer concentration. The compound is a white powder, soluble in water (100 mg/mL), with a purity of ≥99%. It should be stored in a cool, dry place. |
| Molecular Formula |
C9H20N2O5S
|
|---|---|
| Molecular Weight |
268.33
|
| Exact Mass |
268.109
|
| CAS # |
68399-78-0
|
| PubChem CID |
100205
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
158-160°C
|
| Index of Refraction |
1.561
|
| LogP |
-2.59
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
17
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])C([H])(C([H])([H])N1C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])O[H])C([H])([H])C1([H])[H])O[H])(=O)(=O)O[H]
|
| InChi Key |
GIZQLVPDAOBAFN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H20N2O5S/c12-6-5-10-1-3-11(4-2-10)7-9(13)8-17(14,15)16/h9,12-13H,1-8H2,(H,14,15,16)
|
| Chemical Name |
2-hydroxy-3-[4-(2-hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (931.69 mM)
DMSO: 250 mg/mL (931.69 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.17 mg/mL (15.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.17 mg/mL (15.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 4.17 mg/mL (15.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 7: 110 mg/mL (409.94 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7268 mL | 18.6338 mL | 37.2675 mL | |
| 5 mM | 0.7454 mL | 3.7268 mL | 7.4535 mL | |
| 10 mM | 0.3727 mL | 1.8634 mL | 3.7268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
